Ovid Therapeutics stockholders approve 3 proposals at special meeting including authorized share increase to 315M

Ovid Therapeutics Inc.

Approved amendment to increase authorized common shares from 125M to 315M: 34.2M for, 1.5M against, 2.4M abstain.
Approved issuance of shares upon conversion of Series B Preferred and exercise of Series A/B Warrants: 34.3M for, 1.3M against, 2.5M abstain.
Approved issuance of securities to CEO Jeremy Levin under Oct 2, 2025 Securities Purchase Agreement: 34.3M for, 1.2M against, 2.5M abstain.
Special meeting held Dec 11, 2025; quorum 38.0M of 71.2M outstanding shares (53.42%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.